Janet Chandler Dubois MD

Dermatology•Austin, TX

Physician

Join to View Full Profile

8140 North MopacBuilding 3, Suite 120Austin, TX 78759
Phone+1 512-349-9889
Fax+1 512-349-9559

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Dermatology, 1988 - 1991
Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 1987 - 1988
The University of Texas Health Science Center at San AntonioClass of 1987

Certifications & Licensure

TX State Medical License 1995 - 2025
WA State Medical License 1991 - 1994
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis Start of enrollment: 2014 Jan 01
Completed
Phase 2
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis Start of enrollment: 2014 Apr 01
Completed
Phase 2
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis Start of enrollment: 2014 Jun 01
Completed
Phase 2
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris Start of enrollment: 2015 Apr 01
Completed
Phase 2
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Dec 01
Completed
Phase 3
Study of Glycopyrronium in Axillary Hyperhydrosis Start of enrollment: 2015 Jul 01
Completed
Phase 3
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2) Start of enrollment: 2016 Feb 01
Completed
Phase 2
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp Start of enrollment: 2017 Mar 01
Withdrawn
Phase 3
MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Start of enrollment: 2019 Jun 27
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.
Michael Gold, Joel Schlessinger, Greg J Goodman, Steven Dayan, Janet DuBois
Aesthetic Surgery Journal. 2025-03-04
2 citations
Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cmof the face or scalp in patients with actinic keratosis: A phase 3 study.
Neal Bhatia, Edward Lain, Abel Jarell, Janet DuBois, Maria Luisa Tamarit
JAAD International. 2024-12-01
Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomyc...
Amir Tavakkol, Janet C DuBois, Aditya K Gupta
Antimicrobial Agents and Chemotherapy. 2024-10-08

Press Mentions

Promising SK Drug’s Trials Enter Final PhasesMarch 3rd, 2015
Safety of Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities, and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group StudyAugust 21st, 2019
Vial Launches Innovative Dermatology CRO January 27th, 2022

Professional Memberships

American Academy of Dermatology - AAD
Fellow